Clinical trial · Interventional
Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)
γδ T Cell Immunotherapy for Treatment of
NCT02425748CI-TRIAL-00040577completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, effects of γδT cells on human non small lung cancer ( without EGFR mutation) in combination with tumor reducing surgery, for example cryosurgery going to be investigated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DC-CIK | Biological | — | UNRESOLVED |
| γδ T Cell | Biological | — | UNRESOLVED |
| γδ T/DC-CIK cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Group A
- description
- DC-CIK cells will be used against tumor cells.
- interventionNames
- Biological: DC-CIK
- type
- EXPERIMENTAL
- label
- Group B
- description
- γδ T cells will be used against tumor cells.
- interventionNames
- Biological: γδ T Cell
- type
- EXPERIMENTAL
- label
- Group C
- description
- Combination of γδ T cells/ DC-CIK be used against tumor cells.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age:18-75 2. Karnofsky performance status \>50 3. Diagnosis with non small lung tumors based on histology or the current accepted radiological measures. 4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ Will receive cryosurgery, gd Tcells/ DC-CIK. 5. Life expectancy: Greater than 3 months 6. Ability to understand the study protocol and a willingness to sign a written informed consent document Exclusion Criteria: 1. Patients with other kinds of cancer 2. History of coagulation disorders or anemia 3. Patients with heart disease and diabetes
References
Publications (0)
Data not yet available
No reference posted for this study.